Page 3 - Pascal Touchon News Today

StockNews.com initiated coverage on shares of Atara Biotherapeutics (NASDAQ:ATRA – Free Report) in a research note published on Thursday morning. The firm issued a sell rating on the biotechnology company’s stock. Separately, HC Wainwright restated a buy rating and set a $28.00 price target on shares of Atara Biotherapeutics in a research note on Tuesday, […]

Company hopes for approval of drug to treat blood cancer.

HC Wainwright restated their buy rating on shares of Atara Biotherapeutics (NASDAQ:ATRA – Free Report) in a research report sent to investors on Tuesday morning, Benzinga reports. The firm currently has a $28.00 target price on the biotechnology company’s stock. Separately, StockNews.com began coverage on shares of Atara Biotherapeutics in a report on Thursday, August […]

The latest people news happenings over the past month.

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Aug 8, 2023--

31.07.2023 - Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today ...

Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Free Report) was the recipient of a large decrease in short interest during the month of June. As of June 30th, there was short interest totalling 11,700,000 shares, a decrease of 11.4% from the June 15th total of 13,200,000 shares. Based on an average daily volume of 1,940,000 shares, […]

Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Free Report) CEO Pascal Touchon sold 14,291 shares of the stock in a transaction on Tuesday, June 27th. The shares were sold at an average price of $1.66, for a total value of $23,723.06. Following the completion of the transaction, the chief executive officer now directly owns 706,671 shares in […]

Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Free Report) has received a consensus recommendation of “Hold” from the seven research firms that are presently covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company. […]

Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Free Report) CEO Pascal Touchon sold 14,291 shares of Atara Biotherapeutics stock in a transaction that occurred on Tuesday, June 27th. The shares were sold at an average price of $1.66, for a total value of $23,723.06. Following the transaction, the chief executive officer now owns 706,671 shares of the […]